Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with a Fluoropyrimidinein Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction (LYNK-003)